January 23, 2017: Novel Drug Delivery (NDDS) — Sprays, gels, capsules and MEMs, how do they best get where they need to go?
As we undergo major changes in the pharmaceutical sector it is important to remember that industrial transformations are not new in our industry. This presentation will highlight innovation dilemmas we face as they relate to several themes that are important to drug delivery technologies (i.e., Drug Metabolism & Pharmacokinetics, analytical, patient-centered design, business needs, etc.).
Examples will highlight some of the challenges and opportunities the pharmaceutical industry faces concerning the selection and implementation of new technologies related to the needs of patients with the goal of understanding how to get the dosages delivered with better distribution, improved targeting, lower dosages and more (and thus, improved efficacy).
Lastly, we will explore the need to seek patient input to validate our ideas and new processes using approaches that are currently being applied by start-up companies.
- Manuel Sanchez-Felix, Ph.D., FRSC, Senior Fellow, Novel Delivery Technologies, Novartis Institutes for BioMedical Research, Inc.
Dr. Manuel Sanchez-Felix is a Senior Fellow with the Chemical and Pharmaceutical Profiling (CPP) group at the Novartis Institutes for BioMedical Research in Cambridge, MA. He is a scientific leader with over 20 years of experience in Drug Discovery and development where he co-invented and contributed to the successful development and launch of various pharmaceutical products.
At Novartis, Dr. Sanchez-Felix leads a cross-functional group from Discovery and Development that is responsible for Novel Delivery Technologies. His previous position at Novartis involved heading a group of scientists at the interface between Research and Development, establishing physicochemical and biopharmaceutical properties, and combining this information to initiate development strategy and formulation design. Prior to joining Novartis, Manuel was at Eli Lilly & Company for 20 years. His area of expertise includes Biopharmaceutics, drug delivery and patient-centered formulation design. Areas of drug discovery where he has developed products include CNS, infectious diseases (specifically tuberculosis), oncology, bone regeneration, and diabetes.
Dr. Sanchez-Felix received his B.Sc. Honors degree and Ph.D. in Chemistry from the University of Surrey, UK. He is also an Adjunct Professor in the Department of Industrial and Physical Pharmacy at Purdue University (West Lafayette, IN) and a Fellow of the Royal Society of Chemistry. Recently, he joined the Advisory Board for the Biomedical Program at Middlesex Community College and is a member of the Scientific Advisory Board member of an instrument company.
Committee: Jerry Shapiro, Mark Hediger, Carmel Denis, Howard Lin, Bruce Rogers
Co-Chairs, Jerry Shapiro and Barbara Finer
Contact our Chair with questions or if you want to volunteer in some capacity (Jerrold)